906 related articles for article (PubMed ID: 12809958)
1. A randomized, double-blind, placebo-controlled, clinical trial of the effects of pioglitazone on glycemic control and dyslipidemia in oral antihyperglycemic medication-naive patients with type 2 diabetes mellitus.
Herz M; Johns D; Reviriego J; Grossman LD; Godin C; Duran S; Hawkins F; Lochnan H; Escobar-Jiménez F; Hardin PA; Konkoy CS; Tan MH
Clin Ther; 2003 Apr; 25(4):1074-95. PubMed ID: 12809958
[TBL] [Abstract][Full Text] [Related]
2. The impact of pioglitazone on glycemic control and atherogenic dyslipidemia in patients with type 2 diabetes mellitus.
Rosenblatt S; Miskin B; Glazer NB; Prince MJ; Robertson KE;
Coron Artery Dis; 2001 Aug; 12(5):413-23. PubMed ID: 11491207
[TBL] [Abstract][Full Text] [Related]
3. Metabolic effects of pioglitazone in combination with insulin in patients with type 2 diabetes mellitus whose disease is not adequately controlled with insulin therapy: results of a six-month, randomized, double-blind, prospective, multicenter, parallel-group study.
Mattoo V; Eckland D; Widel M; Duran S; Fajardo C; Strand J; Knight D; Grossman L; Oakley D; Tan M;
Clin Ther; 2005 May; 27(5):554-67. PubMed ID: 15978304
[TBL] [Abstract][Full Text] [Related]
4. Effects of pioglitazone and glimepiride on glycemic control and insulin sensitivity in Mexican patients with type 2 diabetes mellitus: A multicenter, randomized, double-blind, parallel-group trial.
Tan M; Johns D; González Gálvez G; Antúnez O; Fabián G; Flores-Lozano F; Zúñiga Guajardo S; Garza E; Morales H; Konkoy C; Herz M;
Clin Ther; 2004 May; 26(5):680-93. PubMed ID: 15220012
[TBL] [Abstract][Full Text] [Related]
5. Metabolic effects of pioglitazone and rosiglitazone in patients with diabetes and metabolic syndrome treated with glimepiride: a twelve-month, multicenter, double-blind, randomized, controlled, parallel-group trial.
Derosa G; Cicero AF; Gaddi A; Ragonesi PD; Fogari E; Bertone G; Ciccarelli L; Piccinni MN
Clin Ther; 2004 May; 26(5):744-54. PubMed ID: 15220018
[TBL] [Abstract][Full Text] [Related]
6. Effects of 1 year of treatment with pioglitazone or rosiglitazone added to glimepiride on lipoprotein (a) and homocysteine concentrations in patients with type 2 diabetes mellitus and metabolic syndrome: a multicenter, randomized, double-blind, controlled clinical trial.
Derosa G; Cicero AF; D'Angelo A; Gaddi A; Ciccarelli L; Piccinni MN; Salvadeo SA; Pricolo F; Ferrari I; Gravina A; Ragonesi PD
Clin Ther; 2006 May; 28(5):679-88. PubMed ID: 16861090
[TBL] [Abstract][Full Text] [Related]
7. Muraglitazar, a dual (alpha/gamma) PPAR activator: a randomized, double-blind, placebo-controlled, 24-week monotherapy trial in adult patients with type 2 diabetes.
Buse JB; Rubin CJ; Frederich R; Viraswami-Appanna K; Lin KC; Montoro R; Shockey G; Davidson JA
Clin Ther; 2005 Aug; 27(8):1181-95. PubMed ID: 16199244
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of therapy with metformin plus pioglitazone in the treatment of patients with type 2 diabetes: a double-blind, placebo-controlled, clinical trial.
Kaku K
Curr Med Res Opin; 2009 May; 25(5):1111-9. PubMed ID: 19309251
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing pioglitazone therapy in patients with type 2 diabetes: a 24-week, multicenter, randomized, double-blind, placebo-controlled, parallel-group study.
Rosenstock J; Brazg R; Andryuk PJ; Lu K; Stein P;
Clin Ther; 2006 Oct; 28(10):1556-68. PubMed ID: 17157112
[TBL] [Abstract][Full Text] [Related]
10. Triple therapy with glimepiride in patients with type 2 diabetes mellitus inadequately controlled by metformin and a thiazolidinedione: results of a 30-week, randomized, double-blind, placebo-controlled, parallel-group study.
Roberts VL; Stewart J; Issa M; Lake B; Melis R
Clin Ther; 2005 Oct; 27(10):1535-47. PubMed ID: 16330290
[TBL] [Abstract][Full Text] [Related]
11. The effect of a thiazolidinedione drug, troglitazone, on glycemia in patients with type 2 diabetes mellitus poorly controlled with sulfonylurea and metformin. A multicenter, randomized, double-blind, placebo-controlled trial.
Yale JF; Valiquett TR; Ghazzi MN; Owens-Grillo JK; Whitcomb RW; Foyt HL
Ann Intern Med; 2001 May; 134(9 Pt 1):737-45. PubMed ID: 11329231
[TBL] [Abstract][Full Text] [Related]
12. Earlier triple therapy with pioglitazone in patients with type 2 diabetes.
Charpentier G; Halimi S;
Diabetes Obes Metab; 2009 Sep; 11(9):844-54. PubMed ID: 19614944
[TBL] [Abstract][Full Text] [Related]
13. Effect of pioglitazone compared with metformin on glycemic control and indicators of insulin sensitivity in recently diagnosed patients with type 2 diabetes.
Pavo I; Jermendy G; Varkonyi TT; Kerenyi Z; Gyimesi A; Shoustov S; Shestakova M; Herz M; Johns D; Schluchter BJ; Festa A; Tan MH
J Clin Endocrinol Metab; 2003 Apr; 88(4):1637-45. PubMed ID: 12679450
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and tolerability of exenatide monotherapy over 24 weeks in antidiabetic drug-naive patients with type 2 diabetes: a randomized, double-blind, placebo-controlled, parallel-group study.
Moretto TJ; Milton DR; Ridge TD; Macconell LA; Okerson T; Wolka AM; Brodows RG
Clin Ther; 2008 Aug; 30(8):1448-60. PubMed ID: 18803987
[TBL] [Abstract][Full Text] [Related]
15. Pioglitazone hydrochloride in combination with metformin in the treatment of type 2 diabetes mellitus: a randomized, placebo-controlled study. The Pioglitazone 027 Study Group.
Einhorn D; Rendell M; Rosenzweig J; Egan JW; Mathisen AL; Schneider RL
Clin Ther; 2000 Dec; 22(12):1395-409. PubMed ID: 11192132
[TBL] [Abstract][Full Text] [Related]
16. Metabolic efficacy and safety of once-daily pioglitazone monotherapy in patients with type 2 diabetes: a double-blind, placebo-controlled study.
Scherbaum WA; Göke B;
Horm Metab Res; 2002 Oct; 34(10):589-95. PubMed ID: 12439788
[TBL] [Abstract][Full Text] [Related]
17. Effect of pioglitazone in combination with insulin therapy on glycaemic control, insulin dose requirement and lipid profile in patients with type 2 diabetes previously poorly controlled with combination therapy.
Berhanu P; Perez A; Yu S
Diabetes Obes Metab; 2007 Jul; 9(4):512-20. PubMed ID: 17587394
[TBL] [Abstract][Full Text] [Related]
18. Sibutramine effect on metabolic control of obese patients with type 2 diabetes mellitus treated with pioglitazone.
Derosa G; D'Angelo A; Salvadeo SA; Ferrari I; Gravina A; Fogari E; Maffioli P; Cicero AF
Metabolism; 2008 Nov; 57(11):1552-7. PubMed ID: 18940393
[TBL] [Abstract][Full Text] [Related]
19. Multicenter retrospective assessment of thiazolidinedione monotherapy and combination therapy in patients with type 2 diabetes: comparative subgroup analyses of glycemic control and blood lipid levels.
Olansky L; Marchetti A; Lau H
Clin Ther; 2003; 25 Suppl B():B64-80. PubMed ID: 14553867
[TBL] [Abstract][Full Text] [Related]
20. The effect of pioglitazone on glycemic and lipid parameters and adverse events in elderly patients with type 2 diabetes mellitus: a post hoc analysis of four randomized trials.
Rajagopalan R; Xu Y; Abbadessa M;
Am J Geriatr Pharmacother; 2006 Jun; 4(2):123-33. PubMed ID: 16860259
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
